{"result": {"took": 806, "timed_out": false, "_shards": {"total": 5, "successful": 5, "skipped": 0, "failed": 0}, "hits": {"total": 2, "max_score": 0.0, "hits": [{"_index": "commoncrawl", "_type": "sentence", "_id": "88942594", "_score": 0.0, "_source": {"text": "[ 54 ] No other atypical studied ( risperidone , quetiapine , and ziprasidone ) did better than the typical perphenazine on the measures used, nor did they produce fewer adverse effects than the typical antipsychotic perphenazine, although more patients discontinued perphenazine owing to extrapyramidal effects compared to the atypical agents (8% vs. 2% to 4%)."}, "highlight": {"text": ["[ 54 ] No other atypical studied ( risperidone , **quetiapine** , and ziprasidone ) did **better** **than** the", " typical **antipsychotic** perphenazine, although more patients discontinued perphenazine owing to"]}}, {"_index": "commoncrawl", "_type": "sentence", "_id": "132527164", "_score": 0.0, "_source": {"text": "A clinical trial carried out under the auspices of the CATIE-AD (Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer Disease) Study Group suggests that the atypical or second-generation antipsychotics, olanzapine, quetiapine, and risperidone, are no better than placebo when given to AD patients."}, "highlight": {"text": ["-generation antipsychotics, olanzapine, **quetiapine**, and risperidone, are no **better** **than** placebo when given to AD patients.", "A clinical trial carried out under the auspices of the CATIE-AD (Clinical **Antipsychotic** Trials of"]}}]}}}